Status:
COMPLETED
Investigate the Safety Tolerability and Pharmacokinetics of Multiple Doses of AZD1236
Lead Sponsor:
AstraZeneca
Conditions:
Healthy Volunteer
Eligibility:
MALE
20-45 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of multiple ascending oral doses of AZD1236 given to healthy young subjects for 13 days and to evaluate the si...
Eligibility Criteria
Inclusion
- Provision of signed informed consent prior to any study specific procedures
- Body Mass Index (BMI) between 19-27 kg/m2
Exclusion
- Receipt of another investigational drug in the 4 months before dosing in this study
- Acute illness which requires medical intervention within 2 weeks of Visit 2.
- Abnormal resting BP and pulse rate (after resting for 10 minutes). Supine blood pressure \> 140 mmHg systolic or \>90 mmHg diastolic, pulse\<= 50 or =\> 90 beats per minute
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00767052
Start Date
September 1 2008
End Date
December 1 2008
Last Update
June 30 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Osaka, Osaka, Japan